Inhibiting BMP9

Presented at Genetics-inspired Therapeutics for PH by Kevin Hart, Pfizer

Summary

This presentation delves into Pfizer's research on inhibiting BMP9 for Pulmonary Hypertension (PH) patients. Initially viewed as protective, BMP9's role shifted to pathogenic, prompting investigation into antagonists. The complex signaling of BMP9 is explored, highlighting its impact on endothelial cell function and vascular health. Data from rat models demonstrates comparable efficacy in blocking ALK1 or BMP9, with promising results for an anti-BMP9 candidate.

Generated by AI, edited by PVRI